Cancer Medicine · global
Which HER2-Positive Breast Cancers Might Be Treated Without Chemotherapy? Five-Year PHERGain Follow-Up Offers New Clues
Among 86 patients selected by imaging and pathological response who received no chemotherapy throughout treatment, five-year invasive disease-free survival was 92.4%. These long-term results support further exploration of treatment de-escalation, but do not yet establish that omitting chemotherapy is as effective as standard therapy.
Can breast cancer treatment become less burdensome while preserving the chance of long-term disease control? The PHERGain trial used tumor responses during treatment to select patients step by step, exploring whether chemotherapy could be omitted in some early-stage HER2-positive breast cancers. Five-year results published in *Nature Medicine* on October 29 provide longer-term follow-up evidence for this approach, while underscoring that identifying suitable patients remains crucial.
PHERGain is a randomized, non-comparative phase 2 trial in which 356 patients were assigned to two groups. Of these, 285 received a response-adapted strategy: treatment began with the two anti-HER2 targeted drugs trastuzumab and pertuzumab, with some patients also receiving endocrine therapy. After two cycles, positron emission tomography (PET) was used to assess changes in tumor metabolism. Patients with an insufficient response had chemotherapy added; those with a good imaging response continued their original therapy until pathological response was confirmed after surgery, which then determined whether chemotherapy would be added.
This selection process had two checkpoints. Patients had to show an early PET response and achieve a pathological complete response in their surgical specimens, meaning no residual invasive cancer cells in the breast or lymph nodes, to avoid chemotherapy throughout treatment. In the study, 86 patients met these criteria, accounting for approximately 30% of the response-adapted group. This strategy therefore still includes surgery and anti-HER2 treatment; a decision to stop medication is not based on a single imaging scan alone.
After a median follow-up of 5.6 years, estimated five-year invasive disease-free survival among these 86 patients was 92.4%, with a 95% confidence interval of 86.7% to 98.5%. One patient experienced distant recurrence during this period. This measure covers events such as invasive recurrence, new cancers, or death, and cannot be directly interpreted as a cure rate. Among all 267 patients in the response-adapted group who underwent surgery as planned, including those who subsequently received chemotherapy, five-year invasive disease-free survival was 89.5%.
The study sponsor, MEDSIR, had already presented the five-year findings at the ESMO Breast 2026 meeting in May. The current paper and OncoDaily’s report published on the same day further explain the limits of interpreting these figures. The chemotherapy-free population of 86 patients was a subgroup selected after randomization on the basis of good treatment response and may already have had a better prognosis. The trial was also not designed to formally establish equivalent efficacy between the two strategies. The 92.4% result can therefore only describe the subsequent disease course in this group; it cannot rule out a potential loss of efficacy from omitting chemotherapy.
The study also explored whether circulating tumor DNA (ctDNA) in the blood could supplement imaging and pathological information. A change from detectable to undetectable ctDNA early in treatment was associated with a higher pathological complete response rate and better long-term outcomes. However, approximately half of the patients whose ctDNA had become undetectable before surgery still had residual disease. The disappearance of the blood signal cannot yet replace surgical pathology and is insufficient on its own as a basis for omitting chemotherapy.
This follow-up gives a more concrete direction to research on treatment de-escalation: using serial assessments to identify tumors that are particularly sensitive to anti-HER2 therapy, then testing whether reducing treatment can maintain disease control. Studies capable of formally comparing efficacy are still needed to establish eligibility criteria and recurrence risks. Whether ctDNA can further improve patient selection also requires prospective validation.